SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Teva Pharmaceuticals
TEVA 20.48+2.2%Oct 31 9:30 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dorine Essey who wrote (300)8/2/2001 4:22:19 PM
From: Dorine Essey   of 340
 
Several drugmakers get OK to sell generic Prozac

--------------------------------------------------------------------------------


NEW YORK, Aug 2 (Reuters) - The U.S. Food and Drug
Administration said it granted approval for several generic
drugmakers to market copycat versions of blockbuster
antidepressant Prozac after patent protection over the drug
expired for Eli Lilly and Co. .
The FDA said Israel's Teva Pharmaceutical Industries Ltd.
received approval to market a liquid oral
solution of the drug in the dosage of 20 milligrams per 5
milliliters. India's Dr. Reddy's Laboratories
was cleared to market a 40 mg. capsule of generic Prozac.
Geneva Pharmaceuticals Inc., a unit of Swiss drug giant
Novartis , received the go-ahead for U.S. sale of a
10 mg. copycat capsule of Prozac. The FDA cleared Alphapharm, a
unit of Germany's Merck KGaA, to market both 10 mg. and 20 mg.
generic tablets of the drug.
Pharmaceutical Resources Inc. has said it would
license the 10 mg. and 20 mg. capsule forms from Alphapharm and
the 40 mg. capsule from Dr. Reddy's.
The approvals came after Barr Laboratories Inc.
said it won approval to market a 20 mg. generic capsule form of
Prozac, which accounts for $2.2 billion of Lilly's $2.7 billion
in annual sales of the drug.


REUTERS
Rtr 15:52 08-02-01
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News